Video

Dr. Hamid Discusses Melanoma Treatment

Author(s):

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses the treatment of melanoma.

Hamid urges community physicians to seek a second opinion when they are unsure about a certain tumor type. After obtaining a second opinion, the patient can then go back to the community oncologist with a therapeutic plan and some expertise behind the decision. In the community, Hamid urges physicians to read up on immunotherapy and its benefits.

However, a physician should not follow a recommendation without considering his or her clinical experience, Hamid says. The physician should also factor in the patient’s desires and have a discussion about toxicities.

Hopefully, the first-line therapy will lead to long-term benefit, Hamid says. If not, either targeted or immunotherapy treatment is available.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD